Please login to the form below

Not currently logged in
Email:
Password:

Celgene forms real-time, real-world trial partnership

Will collaborate with TriNetX, using its electronic medical records network
Celgene

Celgene has struck a deal to use real-time data from electronic medical records to inform the way it designs clinical trials.

It will work with TriNetX to support clinical study and protocol design, site selection and patient recruitment across a range of therapeutic areas and development stages.

Celgene's senior vice president of global clinical research development and operations Jay Kaminski said: “This collaboration is an important part of the innovations we have been making at Celgene to realise the power of data analytics within our clinical research organisation”.

He added: “TriNetX represents the future of a data-driven approach to clinical trial design and research.”

The Cambridge, Massachusetts-based clinical data company has a healthcare institution network that covers over 37 million patients and its systems are set up to analyse patient populations across multiple search criteria.

They then use advanced analytics modules to provide data on which of these criteria have the most impact - including the rate that new patients appear.

While anonymous, the real-time data is traceable to individual patients and so allows clinical researchers to develop virtual patient groups, which can be recreated in a real world clinical trial setting.

Commenting on the partnership, TriNetX's chief executive Gadi Lachman said that the collaboration is a “win-win” for both firms, the network's institutions and patients worldwide.

“Our mission is to disrupt the clinical trial design space by unleashing the power of data that is currently locked away.

“Through our network, healthcare providers, pharma and contract research organisations can create strategic partnerships to improve clinical research and patient care, and we are honoured to have Celgene as part of our network.”

Article by
Rebecca Clifford

25th May 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...